Tyler N. Goddard

Tyler N. Goddard, PhD

(he/him/his)
Patent Agent | Pharmaceutical
617.646.8306 Tyler.Goddard@WolfGreenfield.com

Education

  • BS, Biochemistry, Baylor University
  • PhD, Chemical Biology, Yale University
  • JD, Suffolk University Law School, 2026 Candidate

Key Technologies

  • CRISPR and Gene Editing
  • Biochemistry
  • Nucleic Acid Therapeutics
  • Small Molecule Therapeutics

Practice Groups

Admitted to Practice

  • US Patent and Trademark Office

Location

  • Boston

Overview

Tyler Goddard assists clients with patent preparation and prosecution in the pharmaceutical and biotechnology spaces. Tyler has extensive knowledge and experience in the areas of biochemistry and medicinal chemistry, and his areas of focus include gene editing technologies and small molecule and nucleic acid therapeutics. 

Prior to joining Wolf Greenfield, Tyler obtained his PhD in chemical biology from Yale University. During this time, Tyler was a graduate researcher, where he discovered and characterized the biosynthesis and bioactivities of novel bacterial natural products with anti-inflammatory and antibiotic activities. He also discovered enzymes with potential therapeutic applications in the treatment of aging-associated diseases.

As an undergraduate at Baylor University, Tyler received his BS in biochemistry. As an undergraduate researcher, he worked in a medicinal chemistry lab focused on the synthesis of anti-cancer compounds. 

Tyler is listed as a co-inventor on two patent applications.


Experience

  • Prepared and prosecuted US and foreign patent applications on a wide range biotechnology and pharmaceutical technologies
  • Performed patentability and freedom-to-operate searches and provided advice to clients on the same

Recognition

  • NIH Chemistry-Biology Interface Predoctoral Training Fellow

Publications

  • Goddard, T.N., Patel, J., Park, H.B., Crawford, J.M. Dimeric stilbene antibiotics target the bacterial cell wall in drug-resistant Gram-positive pathogens. Biochemistry. 2020, 59(21), 1966-1971.
  • Park, H.B.*, Goddard, T.N.*, Oh, J., Patel, J., Wei, Z., Perez, C.E., Mercado, B.Q., Wang, R., Wyche, T., Piizzi,G., Flavell, R.A., Crawford, J.M. Bacterial autoimmune drug metabolism transforms an immunomodulator into structurally and functionally divergent antibiotics. Angew Chem Int Ed. 59(20): 7871-7880 
  • Kim, N.Y., Goddard, T.N., Sohn, S., Spiegel, D.A., Crawford, J.M. Biocatalytic reversal of advanced glycation end product modification. ChemBioChem. 2019, 20, 2402-2410